방사선의학 웹진

바로가기  >

Abstract
Forty-seven patients with intrahepatic cholangiocarcinoma (IHCC) who received proton beam therapy (PBT) were analyzed to evaluate the clinical efficacy and safety of hypofractionated PBT in patients with inoperable or recurrent IHCC. The median prescribed dose of PBT was 63.3 GyE (range: 45-80 GyE) in 10 fractions, and the median duration of follow-up in all the patients was 18.3 months (range: 2.4-89.9 months). Disease progression occurred in 35 of the 47 (74.5%) patients; local, intrahepatic, and extrahepatic progression occurred in 5 (10.6%), 20 (42.6%), and 29 (61.7%) patients, respectively. The 2-year freedom from local progression (FFLP), progression-free survival (PFS), overall survival (OS) rates, and median time of OS were 86.9% (95% confidence interval [CI], 74.4-99.4%), 16.8% (95% CI, 4.3-29.3%), 42.7% (95% CI, 28.0-57.4%), and 21.9 months (95% CI, 16.2-28.3 months), respectively; grade ≥ 3 adverse events were observed in four (8.5%) patients. In selected patients with localized disease (no viable tumors outside of the PBT sites), the median time of OS was 33.8 months (95% CI, 5.4-62.3). These findings suggest that hypofractionated PBT is safe and could offer a high rate of FFLP and promising OS in patients with inoperable or recurrent IHCC.

Affiliations

Tae Hyun Kim 1 2, Sang Myung Woo 2, Woo Jin Lee 2, Jung Won Chun 2, Yu Ri Cho 2, Bo Hyun Kim 2, Young-Hwan Koh 2, Sang Soo Kim 1, Eun Sang Oh 1, Do Yeul Lee 1, Sung Uk Lee 1, Yang-Gun Suh 1, Sung Ho Moon 1, Joong-Won Park 2
1Center for Proton Therapy, National Cancer Center, Goyang 10408, Korea.
2Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Korea.